Paul Tudor Jones’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Paul Tudor Jones’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,160,841	Closed	-$5.85M	–	3081
2023 Q1	$5.85M	Buy	+3,160,841	New	+$3.92M	0.09%	310
2017 Q2	–	Sell	-100,000	Closed	-$2.2M	–	1454
2017 Q1	$2.2M	Buy	+100,000	New	+$2.12M	0.07%	180

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Paul Tudor Jones's JNCE Position: Q2 2023 in Review

Paul Tudor Jones sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 3,160,841 shares — an estimated $5.85M sold.

Paul Tudor Jones first reported a position in JNCE in Q1 2017 and held it in 2 quarters. The position peaked at $5.85M in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Paul Tudor Jones reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Paul Tudor Jones sold 3,160,841 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $5.85M.
Paul Tudor Jones first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
Paul Tudor Jones's Jounce Therapeutics, Inc. Common Stock position peaked at $5.85M in Q1 2023.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Tudor Investment Corp's 13F filing for Q2 2023, filed 14 Aug 2023.